- Barrons.com•50 minutes ago
Poor Bristol-Myers Squibb (BMY)--and poor anyone who had been bullish on its shares. It's even more on sale today, however, after Bristol-Myers said that it wouldn't seek accelerated approval of its lung-cancer treatment combination last night, with shares off 10% at $49.94 at 12:05 p.m. today. Credit Suisse analysts Vamil Divan and Barbara Kotei write that the news "removes the possibility for near-term BMY Upside": Bristol-Myers Squibb announced after the close that they have decided to not pursue an accelerated filing strategy for their Opdivo+Yervoy combination in 1st line metastatic/advanced non-small cell lung cancer (NSCLC).
- Reuters - UK Focus•56 minutes ago
Shares (Berlin: DI6.BE - news) of Bristol-Myers Squibb fell nearly 10 percent on Friday following Thursday's announcement that it would not seek accelerated approval of its immunotherapy drug combination in first-line lung cancer, further solidifying Merck & Co (Swiss: MRK-USD.SW - news) 's leading position in the burgeoning immuno-oncolgy field. Lung cancer is by far the biggest oncology market and a handful of companies have been jockeying for position in the battle to become dominant in initial, or first-line, treatment, and to provide much-needed combination therapies. Merck (LSE: 0O14.L - news) shares rose 3.8 percent to $62.60, while Bristol fell to $50.04.
- TheStreet.com•1 hour ago
Here's how to trade seven of the most active stocks on the market this week.
6MK.DE: Summary for MERCK CO. DL-,01 - Yahoo Finance
Merck & Co., Inc. (6MK.DE)
Frankfurt - Frankfurt Delayed price. Currency in EUR
Add to watchlist
|Bid||58.38 x 100000|
|Ask||58.46 x 100000|
|Day's range||58.20 - 59.30|
|52-week range||56.91 - 60.32|
|PE ratio (TTM)||N/A|
|Dividend & yield||N/A (N/A)|
|1y target est||N/A|